Verekitug

Upstream Bio (UPB) will announce Phase 2 VIBRANT trial top-line data for verekitug in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) on September 2, 2025. The global, placebo-controlled study evaluated verekitug, a monoclonal antibody targeting TSLP, administering 100 mg subcutaneously every 12 weeks. The primary endpoint is the change in endoscopic nasal polyp score (NPS) at Week 24. A conference call and webcast will be held at 8:00 a.m. ET to discuss the results. Verekitug is unique for targeting TSLP, a key driver of inflammatory responses.

Upstream Bio announced promising data on verekitug, a lead candidate targeting the TSLP receptor, presented at the EAACI Congress. Modeling data suggests enhanced potency compared to tezepelumab, potentially offering a differentiated profile across inflammatory diseases like asthma, COPD, and CRSwNP. Phase 2 trials for CRSwNP are expected in Q3 2025, followed by severe asthma data in 2026’s first half.